Shots:
Boomray Pharmaceuticals has entered into an exclusive global license agreement with Novartis for an undisclosed preclinical radioligand therapy (RLT) asset
As per the deal, BoomRay will receive ~$900M, incl. an upfront payment as well as development, regulatory, & sales milestone payments, with royalties on future global net sales
Agreement combines BoomRay’s discovery & development capabilities…
